All In Biotech

Drug Trial Radar · NCT07327229

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Feb 27, 2026

Primary completion

Sep 30, 2027

Study completion Apr 30, 2029

Sponsor

Lead sponsor
Antengene Biologics LimitedIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Conditions

  • Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

  • ATG-022Drug

    1.8mg/kg Q3W, every 21 days as one cycle

  • pembrolizumab/KEYTRUDA®Drug

    20mg Q3W, every 21 days as one cycle

  • CAPOXDrug

    Standard Dose level for CAPOX: Capecitabine 1000 mg/m2 PO BID on Day 1-14, Oxaliplatin 130 mg/m2 IV on Day 1, Cycled every 21 days (3 weeks) for 8 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AEs and SAEsTime frame: 12 months after the last subject enrolled
  2. DLTTime frame: Up to 21 Days
  3. RP2DTime frame: Up to 21 Days

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Beijing Cancer hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Provincial Cnacer Hospital

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Gansu Provincial Cnacer Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • Cancer Institute&Hospital Chinese Academy of Medical Sciences

    Langfang, Hebei, China · Not yet recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Anyang Tumor Hospital

    Anyang, Henan, China · Recruiting

  • The First Affiliated Hospital of Henan Medical Hospital

    Xinxiang, Henan, China · Recruiting

  • Henan Cnacer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhenghzou University

    Zhengzhou, Henan, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Recruiting

  • Tongji Medical College of HUST

    Wuhan, Hubei, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China · Recruiting

  • Jinan Central Hospital

    Jinan, Shandong, China · Recruiting

  • Shandong Cancer Hospital &Institue

    Jinan, Shandong, China · Recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Recruiting

  • Tongren Hospital Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanxi provincial cancer hospital

    Taiyuan, Shanxi, China · Recruiting

  • The First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Recruiting

  • The First Affiliated Hospital of XI'AN Jiaotong University

    Xi’an, Shanxi, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Tianjin Medical Universuty Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.